Clinical Trials
Lilly, Vir And GSK Report Positive Topline Data From COVID-19 Trial Of Bamlanivimab With Vir-7831
Eli Lilly and Company, Vir Biotechnology, Inc. and GlaxoSmithKline plc announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients with mild to moderate COVID-19. Results showed that investigational bamlanivimab (LY-CoV555) 700 mg co-administered with...
Press Releases
International Trade Body Warns Over Africa’s Fake Covid Vaccines
Africa’s law enforcement agencies are urged to step up their investment in anti-counterfeiting measures before the trade in fake Covid 19 vaccines spirals out of control.
The advice from the International Hologram Manufacturers Association (IHMA) comes in the wake of...
Packaging & Labelling
Syntegon expands portfolio for the production of parenteral pharmaceuticals
Syntegon Technology has launched the new SVP Essential, a cost-efficient version of its proven Pharmatec SVP process systems for the production of small-volume liquid pharmaceuticals. This portfolio expansion is the response to current industry requirements: “Pharmaceutical manufacturers are increasingly...
Drug Research
Moderna Announces New Supply Agreement with the Philippines for 7 Million Additional Doses of COVID-19 Vaccine Moderna
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the Philippines has secured 7 million additional doses of COVID-19 Vaccine Moderna through a new supply agreement, bringing its confirmed order commitment up to 20...
Clinical Trials
Accenture and Phesi urges pharmaceutical companies to make use of synthetic data in clinical trials
Phesi Inc., a data-driven provider of AI-powered clinical development analytics products and solutions, and Accenture, a global services and consulting company with leading capabilities in digital, cloud, and security, have released the first of a series of reports exploring...
Clinical Trials
CureVac Expands CVnCoV COVID-19 Vaccine Candidate Clinical Trial Analyses to Include Phase 2b/3 Variant Specification
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced plans to expand and further specify the protocols of its ongoing late-stage clinical trials with CVnCoV, its COVID-19 vaccine...
Drug Research
Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance
Evotec SE announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















